Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger S Lo

Showing results (21-30 of 84) with videos related to

Pageof 9
Sort By:
Journal of Translational Medicine|May 26, 2011
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutationsFranziska Niehr, Erika von Euw, Narsis Attar, et al.
Molecular Systems Biology|June 28, 2012
Glucose deprivation activates a metabolic and signaling amplification loop leading to cell deathNicholas A Graham, Martik Tahmasian, Bitika Kohli, et al.
Cell|August 24, 2024
The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistanceJustin L Engel, Xiao Zhang, Mingming Wu, et al.
Molecular Cancer|July 3, 2015
Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanomaDeborah J L Wong, Lidia Robert, Mohammad S Atefi, et al.
Molecular Cancer|August 22, 2014
Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanomaDeborah J L Wong, Lidia Robert, Mohammad S Atefi, et al.
Nature Medicine|April 27, 2023
Multi-organ landscape of therapy-resistant melanomaSixue Liu, Prashanthi Dharanipragada, Shirley H Lomeli, et al.
Plos One|June 23, 2021
Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effectsHelena Escuin-Ordinas, Yining Liu, Lu Sun, et al.
Cancer Discovery|November 23, 2013
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibitionHubing Shi, Aayoung Hong, Xiangju Kong, et al.
Nature|November 26, 2010
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationRamin Nazarian, Hubing Shi, Qi Wang, et al.
Cancer Discovery|May 17, 2012
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitorsHubing Shi, Gatien Moriceau, Xiangju Kong, et al.
Pageof 9

Showing results (21-30 of 84) with videos related to

Sort By:
Pageof 9
Journal of Translational Medicine|May 26, 2011
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutationsFranziska Niehr, Erika von Euw, Narsis Attar, et al.
Molecular Systems Biology|June 28, 2012
Glucose deprivation activates a metabolic and signaling amplification loop leading to cell deathNicholas A Graham, Martik Tahmasian, Bitika Kohli, et al.
Cell|August 24, 2024
The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistanceJustin L Engel, Xiao Zhang, Mingming Wu, et al.
Molecular Cancer|July 3, 2015
Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanomaDeborah J L Wong, Lidia Robert, Mohammad S Atefi, et al.
Molecular Cancer|August 22, 2014
Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanomaDeborah J L Wong, Lidia Robert, Mohammad S Atefi, et al.
Nature Medicine|April 27, 2023
Multi-organ landscape of therapy-resistant melanomaSixue Liu, Prashanthi Dharanipragada, Shirley H Lomeli, et al.
Plos One|June 23, 2021
Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effectsHelena Escuin-Ordinas, Yining Liu, Lu Sun, et al.
Cancer Discovery|November 23, 2013
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibitionHubing Shi, Aayoung Hong, Xiangju Kong, et al.
Nature|November 26, 2010
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationRamin Nazarian, Hubing Shi, Qi Wang, et al.
Cancer Discovery|May 17, 2012
Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitorsHubing Shi, Gatien Moriceau, Xiangju Kong, et al.
Pageof 9